JP2021501578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501578A5 JP2021501578A5 JP2020524196A JP2020524196A JP2021501578A5 JP 2021501578 A5 JP2021501578 A5 JP 2021501578A5 JP 2020524196 A JP2020524196 A JP 2020524196A JP 2020524196 A JP2020524196 A JP 2020524196A JP 2021501578 A5 JP2021501578 A5 JP 2021501578A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- activated
- irradiated feeder
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 50
- 102000000588 Interleukin-2 Human genes 0.000 claims description 42
- 108010002350 Interleukin-2 Proteins 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 239000003112 inhibitor Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 21
- 238000012258 culturing Methods 0.000 claims description 17
- 239000013603 viral vector Substances 0.000 claims description 17
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 108091005685 RIG-I-like receptors Proteins 0.000 claims description 16
- 102000002689 Toll-like receptor Human genes 0.000 claims description 16
- 108020000411 Toll-like receptor Proteins 0.000 claims description 16
- -1 Arekisanokusu Chemical compound 0.000 claims description 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 12
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 12
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims description 12
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims description 12
- 102000001284 I-kappa-B kinase Human genes 0.000 claims description 11
- 108060006678 I-kappa-B kinase Proteins 0.000 claims description 11
- VAVXGGRQQJZYBL-UHFFFAOYSA-N N-[3-[[5-iodo-4-[3-[[oxo(thiophen-2-yl)methyl]amino]propylamino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide Chemical compound N1=C(NCCCNC(=O)C=2SC=CC=2)C(I)=CN=C1NC(C=1)=CC=CC=1NC(=O)N1CCCC1 VAVXGGRQQJZYBL-UHFFFAOYSA-N 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 230000002463 transducing effect Effects 0.000 claims description 6
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 claims description 4
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 claims description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 4
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims description 4
- DHPSFJYFPJRCTN-UHFFFAOYSA-N 5-[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile Chemical compound C=1C=C2NC(=O)CC2=CC=1NC(N=1)=NC=CC=1C(C=C1C#N)=CC=C1N1CCCC1 DHPSFJYFPJRCTN-UHFFFAOYSA-N 0.000 claims description 4
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims description 4
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 4
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 102100028801 Calsyntenin-1 Human genes 0.000 claims description 4
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 claims description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 4
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 4
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 4
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 4
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- UKBGBACORPRCGG-UHFFFAOYSA-N N-[3-[[5-cyclopropyl-2-[3-(4-morpholinylmethyl)anilino]-4-pyrimidinyl]amino]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCCNC(C(=CN=1)C2CC2)=NC=1NC(C=1)=CC=CC=1CN1CCOCC1 UKBGBACORPRCGG-UHFFFAOYSA-N 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims description 4
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims description 4
- 102100035721 Syndecan-1 Human genes 0.000 claims description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 4
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 4
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims description 4
- LEEIJTHMHDMWLJ-CQSZACIVSA-N ethyl (6r)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate Chemical compound CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC1=CC=C(F)C=C1Cl LEEIJTHMHDMWLJ-CQSZACIVSA-N 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 238000003318 immunodepletion Methods 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- ZKZXNDJNWUTGDK-NSCUHMNNSA-N (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide Chemical compound C1=CC(Br)=CC=C1\C=C\CNCCNS(=O)(=O)C1=CC=CC2=CN=CC=C12 ZKZXNDJNWUTGDK-NSCUHMNNSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366493P | 2016-07-25 | 2016-07-25 | |
| US15/801,085 | 2017-11-01 | ||
| US15/801,085 US11293010B2 (en) | 2016-07-25 | 2017-11-01 | Methods of producing modified natural killer cells and methods of use |
| PCT/US2018/058747 WO2019089955A1 (en) | 2016-07-25 | 2018-11-01 | Methods of producing modified natural killer cells and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501578A JP2021501578A (ja) | 2021-01-21 |
| JP2021501578A5 true JP2021501578A5 (enExample) | 2021-12-09 |
| JP7364559B2 JP7364559B2 (ja) | 2023-10-18 |
Family
ID=59656171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503538A Active JP7086928B2 (ja) | 2016-07-25 | 2017-07-25 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
| JP2020524196A Active JP7364559B2 (ja) | 2016-07-25 | 2018-11-01 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503538A Active JP7086928B2 (ja) | 2016-07-25 | 2017-07-25 | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11293010B2 (enExample) |
| EP (2) | EP3487991B1 (enExample) |
| JP (2) | JP7086928B2 (enExample) |
| CN (2) | CN109844099B (enExample) |
| IL (1) | IL273979B2 (enExample) |
| SG (2) | SG11201810871WA (enExample) |
| WO (2) | WO2018022646A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| EP3487991B1 (en) * | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| WO2018104554A1 (en) * | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Improved nk-based cell therapy |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| BR112020016876A2 (pt) * | 2018-02-21 | 2020-12-15 | Board Of Regents, The University Of Texas System | Células apresentadoras de antígeno universal e usos das mesmas |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019222503A1 (en) * | 2018-05-16 | 2019-11-21 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| JP2021524467A (ja) | 2018-05-23 | 2021-09-13 | メニスマート セラピューティクス， インコーポレイテッドＭａｎｙｓｍａｒｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 二重特異性ｔ細胞誘導体及びその使用 |
| WO2019229109A1 (en) * | 2018-05-30 | 2019-12-05 | Glycostem Therapeutics B.V. | Car nk cells |
| US20210230542A1 (en) * | 2018-06-06 | 2021-07-29 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for cell enrichment |
| CN119752801A (zh) * | 2018-08-01 | 2025-04-04 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| CA3110926A1 (en) * | 2018-08-28 | 2020-03-05 | Pharos Vaccine Inc. | Improved lentiviral vector |
| EP3845564A4 (en) * | 2018-08-28 | 2022-05-18 | Immunotech Biopharm Co., Ltd. | ENHANCED THERAPEUTIC T LYMPHOCYTE |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| CN110511912B (zh) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | 免疫细胞的功能调节 |
| WO2020077091A1 (en) * | 2018-10-10 | 2020-04-16 | Wisconsin Alumni Research Foundation | Kir 7.1 gene therapy vectors and methods of using the same |
| CN109402053A (zh) * | 2018-10-17 | 2019-03-01 | 广州元帅生物科技有限公司 | 一种外周血来源单个核细胞的分离及诱导培养方法 |
| CN113891934A (zh) * | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| WO2020172328A1 (en) * | 2019-02-20 | 2020-08-27 | Rutgers, The State University Of New Jersey | Expansion of natural killer and chimeric antigen receptor-modified cells |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| CN113710697A (zh) | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| KR20200110576A (ko) * | 2019-03-15 | 2020-09-24 | 재단법인대구경북과학기술원 | 사이토카인 기반 면역세포 및 그의 면역 치료 용도 |
| EP3712257A1 (en) * | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| BR112021018600B1 (pt) * | 2019-03-21 | 2023-10-17 | Onk Therapeutics Limited | Uso de uma célula nk e seu método de produção |
| CN110079529A (zh) * | 2019-04-28 | 2019-08-02 | 成都美杰赛尔生物科技有限公司 | 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途 |
| CN110106202A (zh) * | 2019-05-07 | 2019-08-09 | 杭州师范大学 | 抗肿瘤nk细胞的制备方法及其细胞与应用 |
| JP2022537162A (ja) * | 2019-06-14 | 2022-08-24 | ジー・テック・バイオ・エルエルシー | 活性化リンパ球細胞ならびにそれを使用してがん及び感染状態を治療する方法 |
| CN110205293A (zh) * | 2019-06-25 | 2019-09-06 | 中冠赛尔生物科技(北京)有限公司 | 一种加强型高效治疗肺癌的nk免疫细胞的制备方法及应用 |
| US20220347216A1 (en) * | 2019-09-13 | 2022-11-03 | Ohio State Innovation Foundation | Nk cell immunotherapy compositions, methods of making and methods of using same |
| US20210077527A1 (en) * | 2019-09-13 | 2021-03-18 | The Research Institute At Nationwide Children's Hospital | Universal donor selection method to identify nk-cell-donors |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021194495A1 (en) | 2020-03-26 | 2021-09-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd28h domain-containing chimeric antigen receptors and methods of use |
| CN113528452B (zh) * | 2020-07-06 | 2023-06-06 | 上海鑫湾生物科技有限公司 | 共表达IL-21和hrCD16嵌合受体的免疫细胞及其应用 |
| EP3964265A1 (en) * | 2020-09-07 | 2022-03-09 | Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof |
| CN112029721A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | 一种活性增强型nk细胞的制备方法 |
| KR102581230B1 (ko) * | 2020-10-16 | 2023-09-21 | 의료법인 성광의료재단 | 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도 |
| CN116802273A (zh) | 2020-11-04 | 2023-09-22 | 美国政府(由卫生和人类服务部的部长所代表) | Ccr5表达减少的经修饰的nk细胞及其使用方法 |
| CN115505572B (zh) * | 2021-06-22 | 2025-11-14 | 康立泰生物医药(青岛)有限公司 | 一种增强型抗肿瘤nk细胞及其制备方法和应用 |
| EP4395837A1 (en) * | 2021-08-30 | 2024-07-10 | CarryGenes Bioengineering, LLC | Safety switches for engineered cells carrying synthetic chromosomes |
| WO2023044304A1 (en) | 2021-09-15 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| CN114306606B (zh) * | 2021-11-29 | 2023-05-26 | 江苏省人民医院（南京医科大学第一附属医院） | cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用 |
| CN114381434A (zh) * | 2022-01-17 | 2022-04-22 | 华东师范大学 | 一种趋化型car-nk细胞及其制备方法和应用 |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
| CN115074325A (zh) * | 2022-07-07 | 2022-09-20 | 广州希灵生物科技有限公司 | Herceptin联合4-1BBL体外扩增NK方法 |
| CN115466726B (zh) * | 2022-09-05 | 2023-09-19 | 北京景达生物科技有限公司 | 一种nk细胞的高效基因转导方案 |
| CN116178566A (zh) * | 2022-09-30 | 2023-05-30 | 深圳博雅感知药业有限公司 | 靶向cd33的嵌合抗原受体和制备b16-cd33 car-nk细胞的方法 |
| CN115975922B (zh) * | 2022-12-15 | 2024-06-28 | 杭州师范大学 | Bx795在制备nk-92细胞激活剂上的应用 |
| WO2024131685A1 (zh) * | 2022-12-19 | 2024-06-27 | 苏州沙砾生物科技有限公司 | 一种细胞培养方法及其用途 |
| WO2024261045A1 (en) | 2023-06-20 | 2024-12-26 | Zelluna Immunotherapy As | Methods of enhancing or modifying nk cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| DE10019075B4 (de) * | 2000-04-18 | 2007-01-18 | Vision 7 Gmbh | Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20090104170A1 (en) | 2004-11-02 | 2009-04-23 | Richard William Wyatt Childs | Compositions and methods for treating hyperproliferative disorders |
| CN101356679A (zh) * | 2005-10-31 | 2009-01-28 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物和方法 |
| US20070264687A1 (en) * | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| CN101684456A (zh) * | 2008-09-28 | 2010-03-31 | 江门罗森生物制药有限公司 | 一种体外培养条件下扩增人nk细胞的方法 |
| JP5923037B2 (ja) * | 2009-06-17 | 2016-05-24 | トカジェン インコーポレーテッド | 複製可能レトロウイルスベクターの産生細胞 |
| CN104853766A (zh) * | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| EP2793026A1 (en) * | 2013-04-18 | 2014-10-22 | Centre National de la Recherche Scientifique (CNRS) | New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation |
| AU2014259675B2 (en) * | 2013-05-03 | 2019-05-02 | Ohio State Innovation Foundation | CS1-specific chimeric antigen receptor engineered immune effector cells |
| WO2015112793A2 (en) * | 2014-01-27 | 2015-07-30 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| WO2016073595A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | T cells and dendritic cells for polyomavirus therapy |
| US10813952B2 (en) | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| US10815457B2 (en) * | 2014-11-24 | 2020-10-27 | University Of Pittsburgh Of The Commonwealth Systems Of Higher Education | Active CXCR4+ immune cells and methods for their production and use |
| HUE056374T2 (hu) * | 2015-09-30 | 2022-02-28 | Vycellix Inc | Fokozott génbevitel természetes ölõsejtekbe, hematopoetikus õssejtekbe és makrofágokba |
| CN105567634A (zh) * | 2016-01-27 | 2016-05-11 | 上海润泉生物技术有限公司 | 一种用于nk细胞体外扩增的培养基及nk细胞体外扩增的方法 |
| US20200392457A1 (en) * | 2016-07-25 | 2020-12-17 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of producing modified natural killer cells and methods of use |
| EP3487991B1 (en) | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| CN106350487B (zh) * | 2016-09-13 | 2019-01-25 | 北京多赢时代转化医学研究院 | 联合制备car-nk细胞和car-nkt细胞的方法 |
| KR20190100200A (ko) * | 2016-11-22 | 2019-08-28 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
-
2017
- 2017-07-25 EP EP17754517.5A patent/EP3487991B1/en active Active
- 2017-07-25 SG SG11201810871WA patent/SG11201810871WA/en unknown
- 2017-07-25 WO PCT/US2017/043774 patent/WO2018022646A1/en not_active Ceased
- 2017-07-25 JP JP2019503538A patent/JP7086928B2/ja active Active
- 2017-07-25 CN CN201780046354.1A patent/CN109844099B/zh active Active
- 2017-11-01 US US15/801,085 patent/US11293010B2/en active Active
-
2018
- 2018-11-01 SG SG11202003201QA patent/SG11202003201QA/en unknown
- 2018-11-01 EP EP18811415.1A patent/EP3704231A1/en active Pending
- 2018-11-01 IL IL273979A patent/IL273979B2/en unknown
- 2018-11-01 CN CN201880071474.1A patent/CN111344395B/zh active Active
- 2018-11-01 JP JP2020524196A patent/JP7364559B2/ja active Active
- 2018-11-01 WO PCT/US2018/058747 patent/WO2019089955A1/en not_active Ceased
-
2022
- 2022-03-07 US US17/688,435 patent/US12448604B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501578A5 (enExample) | ||
| IL273979B2 (en) | Methods of producing modified natural killer cells and methods of use | |
| US20240316107A1 (en) | Compositions and Methods for Gene Editing in T Cells Using CRISPR/Cpf1 | |
| JP2019523001A5 (enExample) | ||
| CN112969793B (zh) | 经修饰的t细胞、其制备方法及用途 | |
| Zhang et al. | Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside | |
| CN107206100B (zh) | 自然杀伤细胞的方法和组合物 | |
| CN107922925B (zh) | 用于自然杀伤细胞扩增的方法 | |
| Ptáčková et al. | A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21 | |
| Meng et al. | Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells | |
| US20240316102A1 (en) | Engineered natural killer (nk) cells and related methods | |
| Wu et al. | Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy | |
| CN109797171A (zh) | 经修饰的t细胞、其制备方法及用途 | |
| CN111566221A (zh) | 用于nk细胞转导的方法 | |
| TW202102667A (zh) | 用於擴增和分化供過繼性細胞治療之ｔ淋巴細胞和天然殺手（ｎｋ）細胞之方法 | |
| CN114517185B (zh) | 嵌合抗原受体nk细胞及其制备方法和应用 | |
| JP2024045306A (ja) | 胚性間葉系始原細胞の製造方法及び使用方法 | |
| EP4269595A2 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| JP7692226B2 (ja) | モノボディベースのキメラ抗原受容体及びそれを含む免疫細胞 | |
| JPWO2016002760A1 (ja) | Ｂ細胞集団の製造方法 | |
| Deol et al. | Comparative evaluation of synthetic cytokines for enhancing production and performance of NK92 cell-based therapies | |
| US20220041984A1 (en) | Mobilized peripheral blood as a source of modified immune cells | |
| CN116904514B (zh) | 用双aav载体同步定点基因编辑制备car-t细胞的方法 | |
| WO2025242168A1 (en) | Methods of making cells expressing an engineered receptor | |
| Han et al. | Pluripotent stem cell-derived chimeric antigen receptor-natural killer cells targeting epidermal growth factor receptor 2 for cancer immunotherapy |